Eagle Pharmaceuticals plans to delist from Nasdaq and SEC to reduce reporting obligations.

From GlobeNewswire: 2024-11-15 17:00:00

Eagle Pharmaceuticals, Inc. announced its intent to delist its common stock from the Nasdaq Global Market, filing its own Form 25 with the SEC. The Common Stock has been trading on the OTC Expert Market since October 4, 2024. The company anticipates filing the Form 25 on or after November 25, 2024. This move will reduce certain SEC reporting obligations. Eagle Pharmaceuticals is a fully integrated pharmaceutical company focused on developing innovative medicines for various disease states. Forward-looking statements caution investors about potential risks and uncertainties, urging caution when interpreting the information. Investor Relations contact information is available for further inquiries.



Read more at GlobeNewswire: Eagle Announces Update on Delisting from Nasdaq and SEC